18-APR-2026 6:10

ERLYTX ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 1 Y 1 Platinum/Etoposide + Atezo Induction + Maintenance 189 53 19 8 4 1 0 06/28/2022 266 77
        2 Platinum/Etoposide + Atezo Induction   49 19 10 6 0 0      
        3 Platinum/Etoposide Only   47 18 8 4 2 0      
            149 56 26 14 3 0      
 
  SN2426-cSCC, IC Met/Inop, Amivantamab v Cetuximab 1 Y 1 Amivantamab and hyaluronidase (Safety Run-in) 86 3 3 3 3 3 1 03/23/2026 55 14
            3 3 3 3 3 1      
 
  21CTP.HN01-HN, Recur/Met, Amivantamab + Chemo 1 Y 1 Amivantamab + Carboplatin + Paclitaxel 50 2 2 2 2 2 0 03/25/2026    
            2 2 2 2 2 0      
 
  EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib 1 T 1 Paclitaxel + Ipatasertib 33 33 13 1 0 0 0 09/22/2023 207 66
            33 13 1 0 0 0      
 
Yes A071401-Prog Meningiomas,SMO/AKT/NF2 Inhib 0 E Total Registrations   53 3 1 0 0 0 02/22/2016 292 85
            53 3 1 0 0 0      
 
    1 E Total Registrations   9 1 0 0 0 0 02/22/2016    
            9 1 0 0 0 0      
 
No AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 1 E Total Registrations   5 2 1 1 1 0 10/07/2021 216 116
            5 2 1 1 1 0      
 
  EA7211-Sarc, Hi-Risk RetroPeritoneal, Neo+Sur 1 E Total Registrations   2 2 2 2 2 0 03/24/2026    
            2 2 2 2 2 0      
 
  EAY191-ComboMATCH 1 E Total Registrations   21 8 1 0 0 0 08/03/2023 348 127
            21 8 1 0 0 0      
 

18-APR-2026 6:10

ERLYTX Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 2 Late Randomization Callback 08-May-17 216 116
EAY191 ComboMATCH 2 Re-Screening 06-Mar-23 348 127